Variants in activators and downstream targets of ATM, radiation exposure, and contralateral breast cancer risk in the WECARE study

✍ Scribed by Jennifer D. Brooks; Sharon N. Teraoka; Anne S. Reiner; Jaya M. Satagopan; Leslie Bernstein; Duncan C. Thomas; Marinela Capanu; Marilyn Stovall; Susan A. Smith; Shan Wei; Roy E. Shore; John D. Boice Jr.; Charles F. Lynch; Lene Mellemkjær; Kathleen E. Malone; Xiaolin Liang; the WECARE Study Collaborative Group; Robert W. Haile; Patrick Concannon; Jonine L. Bernstein

• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 179 KB
• Volume: 33
• Category: Article
• ISSN: 1059-7794
• DOI: 10.1002/humu.21604

✦ Synopsis

Ionizing radiation (IR) is a breast carcinogen that induces DNA double-strand breaks (DSBs), and variation in genes involved in the DNA DSB response has been implicated in radiation-induced breast cancer. The Women's Environmental, Cancer, and Radiation Epidemiology (WECARE) study is a populationbased study of cases with contralateral breast cancer (CBC) and matched controls with unilateral breast cancer. The location-specific radiation dose received by the contralateral breast was estimated from radiotherapy records and mathematical models. One hundred fifty-two SNPs in six genes (CHEK2, MRE11A, MDC1, NBN, RAD50, TP53BP1) involved in the DNA DSBs response were genotyped. No variants or haplotypes were associated with CBC risk (649 cases and 1,284 controls) and no variants were found to interact with radiation dose. Carriers of a RAD50 haplotype exposed to ≥1 gray (Gy) had an increased risk of CBC compared with unexposed carriers (Rate ratios [RR] = 4.31 [95% confidence intervals [CI] 1.93-9.62]); with an excess relative risk (ERR) per Gy = 2.13 [95% CI 0.61-5.33]). Although the results of this study were largely null, carriers of a haplotype in RAD50 treated with radiation had a greater CBC risk than unexposed carriers.